Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection.
JournalMolecular medicine (Cambridge, Mass.)
MetadataShow full item record
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel type b coronavirus responsible for the COVID-19 pandemic. With over 224 million confirmed infections with this virus and more than 4.6 million people dead because of it, it is critically important to define the immunological processes occurring in the human response to this virus and pathogenetic mechanisms of its deadly manifestation. This perspective focuses on the contribution of the recently discovered interaction of SARS-CoV-2 Spike protein with neuropilin 1 (NRP1) receptor, NRP1 as a virus entry receptor for SARS-CoV-2, its role in different physiologic and pathologic conditions, and the potential to target the Spike–NRP1 interaction to combat virus infectivity and severe disease manifestations. © 2021, The Author(s).
Rights/Terms© 2021. The Author(s).
KeywordACE2, angiotensin converting enzyme 2
COVID-19, coronavirus disease 2019
CendR C-end rule
Host immune response
Immunotargets and strategies
RBD, receptor-biding domain
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17614
- Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
- Authors: Day CJ, Bailly B, Guillon P, Dirr L, Jen FE, Spillings BL, Mak J, von Itzstein M, Haselhorst T, Jennings MP
- Issue date: 2021 Mar 30
- Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
- Authors: Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Österlund P, Joensuu M, Meunier FA, Butcher SJ, Winkler MS, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M
- Issue date: 2020 Nov 13
- SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment.
- Authors: Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, Jiang S, Demeter J, Bevacqua RJ, Chang CA, Whitener RL, Stalder AK, Zhu B, Chen H, Goltsev Y, Tzankov A, Nayak JV, Nolan GP, Matter MS, Andino R, Jackson PK
- Issue date: 2021 Aug 3
- Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
- Authors: Yang LJ, Chen RH, Hamdoun S, Coghi P, Ng JPL, Zhang DW, Guo X, Xia C, Law BYK, Wong VKW
- Issue date: 2021 Jul
- Neuropilin-1 is a host factor for SARS-CoV-2 infection.
- Authors: Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Antón-Plágaro C, Shoemark DK, Simón-Gracia L, Bauer M, Hollandi R, Greber UF, Horvath P, Sessions RB, Helenius A, Hiscox JA, Teesalu T, Matthews DA, Davidson AD, Collins BM, Cullen PJ, Yamauchi Y
- Issue date: 2020 Nov 13